Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Mar 28 04:00PM ET
56.97
Dollar change
-0.15
Percentage change
-0.26
%
IndexS&P 500 P/E21.54 EPS (ttm)2.64 Insider Own1.19% Shs Outstand224.29M Perf Week-1.30%
Market Cap12.79B Forward P/E10.64 EPS next Y5.35 Insider Trans-0.35% Shs Float221.85M Perf Month-5.02%
Income597.60M PEG0.96 EPS next Q0.86 Inst Own99.05% Short Float3.56% Perf Quarter-9.11%
Sales3.70B P/S3.46 EPS this Y25.25% Inst Trans0.60% Short Ratio4.62 Perf Half Y-3.62%
Book/sh23.14 P/B2.46 EPS next Y21.20% ROA9.41% Short Interest7.91M Perf Year-18.97%
Cash/sh16.28 P/C3.50 EPS next 5Y22.50% ROE12.50% 52W Range50.27 - 76.04 Perf YTD-9.27%
Dividend Est.- P/FCF27.57 EPS past 5Y38.99% ROI11.42% 52W High-25.08% Beta0.65
Dividend TTM- Quick Ratio3.69 Sales past 5Y14.55% Gross Margin91.47% 52W Low13.33% ATR (14)1.31
Dividend Ex-Date- Current Ratio3.75 EPS Y/Y TTM73.98% Oper. Margin17.64% RSI (14)41.41 Volatility1.67% 2.30%
Employees2524 Debt/Eq0.01 Sales Y/Y TTM8.87% Profit Margin16.17% Recom1.96 Target Price74.59
Option/ShortYes / Yes LT Debt/Eq0.01 EPS Q/Q602.37% Payout0.00% Rel Volume1.10 Prev Close57.12
Sales Surprise1.06% EPS Surprise-7.85% Sales Q/Q9.35% EarningsFeb 13 BMO Avg Volume1.71M Price56.97
SMA20-2.62% SMA50-3.77% SMA200-5.11% Trades Volume1,883,103 Change-0.26%
Date Action Analyst Rating Change Price Target Change
Feb-23-24Initiated Jefferies Buy $81
Feb-14-24Downgrade JMP Securities Mkt Outperform → Mkt Perform
Dec-13-23Upgrade Leerink Partners Market Perform → Outperform $78
Dec-04-23Upgrade Guggenheim Neutral → Buy $86
Nov-21-23Downgrade Goldman Buy → Neutral $98 → $65
Jul-25-23Initiated Citigroup Buy $82
May-04-23Downgrade BofA Securities Buy → Neutral $84
Apr-10-23Downgrade RBC Capital Mkts Outperform → Sector Perform $81 → $79
Mar-24-23Upgrade SVB Securities Underperform → Market Perform $61
Jan-31-23Initiated Piper Sandler Overweight $100
Mar-26-24 02:47PM
Mar-17-24 08:50AM
Mar-15-24 10:37AM
Mar-14-24 11:30AM
08:18AM
01:52PM Loading…
Mar-12-24 01:52PM
Mar-11-24 01:02PM
07:18AM
Mar-10-24 04:05PM
04:05PM
Mar-07-24 03:00PM
Mar-04-24 08:00AM
Mar-03-24 08:29AM
Feb-29-24 10:19AM
07:30AM
01:10PM Loading…
Feb-28-24 01:10PM
Feb-27-24 04:08PM
Feb-26-24 03:20PM
Feb-21-24 04:50PM
Feb-15-24 08:00AM
Feb-14-24 09:32AM
01:15AM
12:12AM
Feb-13-24 05:43PM
11:37AM
09:30AM
08:26AM
08:25AM
07:38AM
07:35AM
07:34AM Loading…
07:34AM
07:00AM
Feb-09-24 11:03AM
09:15AM
Feb-07-24 08:55AM
Feb-06-24 04:30AM
Feb-05-24 06:54PM
04:46PM
Jan-31-24 07:33PM
Jan-30-24 11:07AM
Jan-26-24 09:12AM
Jan-24-24 08:39AM
Jan-23-24 08:00AM
Jan-18-24 04:00PM
Jan-08-24 08:30AM
Jan-06-24 11:02AM
Jan-02-24 07:19PM
Dec-20-23 01:50PM
Dec-19-23 11:41AM
Dec-15-23 02:30PM
Dec-12-23 12:46PM
08:00AM
Dec-10-23 05:00PM
Dec-05-23 10:32AM
Nov-30-23 11:31AM
Nov-16-23 12:17PM
Nov-13-23 09:50PM
Nov-12-23 08:18AM
Nov-09-23 10:01PM
Nov-02-23 09:00AM
Nov-01-23 12:32PM
Oct-31-23 09:52PM
12:14PM
09:36AM
09:30AM
08:43AM
08:15AM
07:09AM
07:00AM
Oct-30-23 11:37AM
Oct-27-23 11:36AM
08:00AM
Oct-25-23 10:02AM
Oct-20-23 12:04PM
Oct-18-23 08:00AM
Oct-16-23 08:00AM
07:30AM
Oct-13-23 12:44PM
10:30AM
08:00AM
Oct-12-23 11:29AM
09:00AM
Oct-11-23 10:30AM
09:15AM
08:15AM
Oct-10-23 04:45PM
08:00AM
Sep-29-23 01:43PM
Sep-26-23 12:33PM
Sep-21-23 07:11PM
Sep-20-23 12:12PM
Sep-18-23 04:07PM
11:36AM
09:59AM
Aug-31-23 11:31AM
Aug-22-23 08:00AM
Aug-08-23 06:20AM
Aug-04-23 04:33PM
Aug-02-23 07:32PM
Aug-01-23 05:00PM
Incyte Corp. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of proprietary therapeutics. It focuses on hematology and oncology, and inflammation and autoimmunity therapeutic areas. The company was founded in April 1991 and is headquartered in Wilmington, DE.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Stein Steven HEVP & Chief Medical OfficerJan 03 '24Sale65.517,365482,48190,218Jan 05 12:27 PM
Iyengar Vijay KEVP, GMAPPSJan 02 '24Sale65.0065742,70543,412Jan 04 01:05 PM
Tray ThomasPrincipal Accounting OfficerDec 13 '23Sale62.371,06766,54923,436Dec 14 02:11 PM
Tray ThomasPrincipal Accounting OfficerDec 12 '23Sale57.3621012,04624,503Dec 14 02:11 PM
SWAIN PAULA JEVP, Human ResourcesSep 01 '23Sale65.138,449550,28377,530Sep 06 04:00 PM
Stein Steven HEVP & Chief Medical OfficerAug 01 '23Sale63.2821,5111,361,21697,583Aug 03 04:00 PM
Last Close
Mar 28 04:00PM ET
267.04
Dollar change
+8.23
Percentage change
3.18
%
MDGL Madrigal Pharmaceuticals Inc daily Stock Chart
IndexRUT P/E- EPS (ttm)-19.94 Insider Own18.78% Shs Outstand19.88M Perf Week4.61%
Market Cap5.31B Forward P/E- EPS next Y-14.14 Insider Trans12.22% Shs Float16.16M Perf Month5.04%
Income-373.63M PEG- EPS next Q-6.23 Inst Own93.67% Short Float20.18% Perf Quarter12.79%
Sales0.00M P/S- EPS this Y-16.32% Inst Trans-1.70% Short Ratio5.80 Perf Half Y76.29%
Book/sh20.39 P/B13.09 EPS next Y39.20% ROA-74.49% Short Interest3.26M Perf Year10.90%
Cash/sh31.87 P/C8.38 EPS next 5Y0.00% ROE-123.98% 52W Range119.76 - 322.67 Perf YTD15.41%
Dividend Est.- P/FCF- EPS past 5Y-55.24% ROI-71.58% 52W High-17.24% Beta-0.47
Dividend TTM- Quick Ratio5.38 Sales past 5Y0.00% Gross Margin- 52W Low122.98% ATR (14)17.41
Dividend Ex-Date- Current Ratio5.38 EPS Y/Y TTM-15.71% Oper. Margin0.00% RSI (14)56.75 Volatility5.06% 6.59%
Employees376 Debt/Eq0.29 Sales Y/Y TTM- Profit Margin- Recom1.29 Target Price394.54
Option/ShortYes / Yes LT Debt/Eq0.29 EPS Q/Q-13.93% Payout- Rel Volume0.78 Prev Close258.81
Sales Surprise- EPS Surprise-8.42% Sales Q/Q- EarningsFeb 28 BMO Avg Volume562.63K Price267.04
SMA204.28% SMA5013.12% SMA20032.34% Trades Volume441,051 Change3.18%
Date Action Analyst Rating Change Price Target Change
Mar-15-24Upgrade B. Riley Securities Sell → Neutral $155 → $270
Mar-06-24Initiated Citigroup Buy $382
Feb-26-24Downgrade B. Riley Securities Neutral → Sell $155
Dec-20-22Reiterated Oppenheimer Outperform $170 → $250
Dec-19-22Upgrade Raymond James Underperform → Mkt Perform
Dec-19-22Reiterated Piper Sandler Overweight $203 → $280
Dec-19-22Reiterated H.C. Wainwright Buy $170 → $225
Jul-08-22Downgrade B. Riley Securities Buy → Neutral $131 → $75
Oct-07-21Initiated Jefferies Buy $151
Aug-06-21Upgrade BMO Capital Markets Market Perform → Outperform
Today 04:43AM
Mar-26-24 09:53AM
Mar-22-24 06:15AM
Mar-19-24 05:50AM
Mar-18-24 11:58PM
08:01PM Loading…
08:01PM
04:47PM
04:12PM
04:04PM
03:15PM
07:00AM
Mar-17-24 08:50AM
05:50AM
Mar-15-24 04:35PM
04:14PM
03:50PM Loading…
03:50PM
02:34PM
01:45PM
12:56PM
12:09PM
10:17AM
10:01AM
09:30AM
07:45AM
05:35AM
Mar-14-24 04:25PM
04:15PM
12:11PM
Mar-09-24 05:52AM
Mar-06-24 04:05PM
08:00AM Loading…
Mar-05-24 08:00AM
06:03AM
Feb-28-24 07:01AM
07:00AM
06:45AM
Feb-26-24 04:04PM
10:52AM
Feb-23-24 05:43AM
Feb-21-24 08:00AM
Feb-13-24 01:36PM
Feb-08-24 08:00AM
Feb-06-24 04:05PM
11:29AM
11:28AM
Jan-29-24 08:00AM
02:59AM
Jan-22-24 08:00AM
01:29AM
Jan-04-24 08:00AM
01:21AM
Jan-03-24 04:30PM
Dec-30-23 06:50AM
Dec-22-23 04:30PM
Dec-19-23 01:02PM
10:16AM
Dec-15-23 11:01PM
Dec-07-23 08:45AM
Nov-27-23 04:30PM
09:50AM
Nov-24-23 10:00AM
Nov-21-23 08:00AM
Nov-17-23 10:46AM
Nov-16-23 03:03PM
Nov-15-23 04:45PM
Nov-14-23 10:56AM
Nov-13-23 04:40PM
Nov-10-23 08:00AM
07:30AM
Nov-07-23 04:54AM
Nov-06-23 08:00AM
06:29AM
Nov-04-23 12:16PM
Nov-02-23 04:05PM
Oct-27-23 10:01AM
Oct-17-23 09:53AM
Oct-12-23 04:05PM
07:49AM
Oct-02-23 11:51AM
Sep-29-23 12:41PM
Sep-28-23 10:30PM
04:01PM
Sep-27-23 09:53AM
Sep-25-23 08:08PM
Sep-21-23 09:25AM
09:25AM
01:00AM
Sep-20-23 07:00AM
Sep-14-23 04:30PM
Sep-13-23 04:10PM
09:10AM
Sep-11-23 07:00AM
Sep-09-23 03:59PM
Sep-04-23 03:43PM
Aug-30-23 08:54AM
Aug-23-23 06:40AM
Aug-14-23 07:02PM
Aug-08-23 08:50AM
08:00AM
Jul-17-23 08:00AM
Jul-10-23 09:32AM
Madrigal Pharmaceuticals, Inc. engages on the development and commercialization of innovative therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product, MGL-3196, is used for the treatment of non-alcoholic steatohepatitis and familial hypercholesterolemia. The company was founded by Rebecca Taub and Edward Chiang on September 2011 and is headquartered in Fort Washington, PA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Waltermire Robert E.Senior VP, Chief Pharma Dev.Dec 15 '23Option Exercise87.922,000175,8407,667Dec 18 04:30 PM
Waltermire Robert E.Senior VP, Chief Pharma Dev.Dec 15 '23Sale238.502,000477,0005,667Dec 18 04:30 PM
Waltermire Robert E.Senior VP, Chief Pharma Dev.Dec 14 '23Option Exercise87.922,000175,8407,667Dec 18 04:30 PM
BAKER BROS. ADVISORS LPDirectorDec 14 '23Buy228.3220,6334,710,8931,793,403Dec 14 06:10 PM
Waltermire Robert E.Senior VP, Chief Pharma Dev.Dec 14 '23Sale232.502,000465,0005,667Dec 18 04:30 PM
Waltermire Robert E.Senior VP, Chief Pharma Dev.Dec 13 '23Option Exercise87.922,500219,8008,167Dec 14 04:30 PM
BAKER BROS. ADVISORS LPDirectorDec 13 '23Buy219.3981,15917,805,6841,774,294Dec 14 06:10 PM
Waltermire Robert E.Senior VP, Chief Pharma Dev.Dec 13 '23Sale225.402,500563,5005,667Dec 14 04:30 PM
Waltermire Robert E.Senior VP, Chief Pharma Dev.Dec 12 '23Option Exercise87.921,300114,2966,967Dec 14 04:30 PM
BAKER BROS. ADVISORS LPDirectorDec 12 '23Buy218.3134,5787,548,6161,699,129Dec 14 06:09 PM
Waltermire Robert E.Senior VP, Chief Pharma Dev.Dec 12 '23Sale217.851,300283,2005,667Dec 14 04:30 PM
Lynch Brian JosephSVP and General CounselDec 05 '23Option Exercise87.091,00087,09016,001Dec 06 04:30 PM
Lynch Brian JosephSVP and General CounselDec 05 '23Sale227.331,000227,33015,001Dec 06 04:30 PM
Lynch Brian JosephSVP and General CounselDec 04 '23Option Exercise81.161,800146,09016,801Dec 06 04:30 PM
Lynch Brian JosephSVP and General CounselDec 04 '23Sale218.871,800393,96415,001Dec 06 04:30 PM
Lynch Brian JosephSVP and General CounselNov 30 '23Option Exercise73.753,000221,25018,001Dec 01 04:30 PM
Lynch Brian JosephSVP and General CounselNov 30 '23Sale204.583,000613,73015,001Dec 01 04:30 PM
Lynch Brian JosephSVP and General CounselNov 29 '23Option Exercise73.754,000295,00019,001Dec 01 04:30 PM
Lynch Brian JosephSVP and General CounselNov 29 '23Sale199.194,000796,75015,001Dec 01 04:30 PM
BAKER BROS. ADVISORS LPDirectorNov 21 '23Buy188.4764,35012,128,3401,667,104Nov 21 06:15 PM
BAKER BROS. ADVISORS LPDirectorNov 20 '23Buy185.7420,7093,846,5751,607,668Nov 21 06:14 PM
BAKER BROS. ADVISORS LPDirectorNov 17 '23Buy174.7046,3708,100,7041,588,541Nov 21 06:14 PM
BAKER BROS. ADVISORS LPDirectorNov 15 '23Buy161.9715,1992,461,7211,545,775Nov 15 05:13 PM
BAKER BROS. ADVISORS LPDirectorNov 14 '23Buy154.0037,6605,799,6531,500,227Nov 15 05:12 PM
BAKER BROS. ADVISORS LPDirectorNov 14 '23Buy156.4234,1885,347,8371,531,757Nov 15 05:13 PM
BAKER BROS. ADVISORS LPDirectorNov 13 '23Buy143.2169,83910,001,3681,465,494Nov 15 05:12 PM